 |
[Alpha Biz=(Chicago) Reporter Paul Lee] "Although it is late, 27 companies will work together to make it successful with new drug development modality (treatment technology)."
Chun Jong-sik, CEO of CJ Bioscience, made the remarks at the launching ceremony of the Microbiome New Drug Business Council held at COEX in Gangnam-gu, Seoul on the 13th. CJ Bioscience will be the first chairman of the council for the next two years.
CEO Chun expressed confidence in the domestic microbiome R&D capabilities, saying, "Although the global situation is not easy, the technological competitiveness of domestic microbiome companies is also recognized overseas."
GobioLab, Genome & Company, Chong Kun Dang Bio, HEM Pharma and Immunbiome will serve as the steering committee members of the council, with a total of 27 companies participating in the council.
The council will not only promote the microbiome industry but also suggest various regulatory innovation and policy improvements to the government. It also plans to seek win-win measures among council members.
Currently, there are only two microbiome-based treatments approved by the US Food and Drug Administration (FDA).
In November last year, FDA approved REBYOTA, a treatment for clostridium difficile infections (CDI) jointly developed by Leviomics of the United States and Fering Biopharmaceuticals of Switzerland, as the first microbiome treatment. It is a treatment that is administered to the rectum.
In April, Vowst, an oral microbiome intestinal disease treatment by US bio company Ceres Therapeutics, was approved by the FDA.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
